Trial Profile
A retrospective study of first line bevacizumab or cetuximab containing regimens assessing treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Apr 2016 New trial record